Amplifying tumour-specific replication lesions by DNA repair inhibitors - A new era in targeted cancer therapy

European Journal of Cancer

Volumn 44, Issue 7, 2008, Pages 921-927

  Helleday, Thomas ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Anti cancer treatments; DNA repair; Hypoxia; Oncogenes; Replication lesions

Indexed keywords

DNA;

ARTICLE; CANCER CELL; CANCER THERAPY; DNA REPAIR; DNA REPLICATION; GENE AMPLIFICATION; GENE EXPRESSION; HYPOXIA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; HUMANS; MUTATION; NEOPLASMS; ONCOGENES; TARGETED GENE REPAIR;

EID: 42649123980     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.02.044     Document Type: Article

References (62)

1. Tabancay Jr. A.P., and Forsburg S.L. Eukaryotic DNA replication in a chromatin context. Curr Top Dev Biol 76 (2006) 129-184
2. Jorgensen S., Elvers I., Trelle M.B., et al. The histone methyltransferase SET8 is required for S-phase progression. J Cell Biol 179 7 (2007) 1337-1345
3. Tardat M., Murr R., Herceg Z., Sardet C., and Julien E. PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol 179 7 (2007) 1413-1426
4. Gottipati P., Cassel T.N., Savolainen L., and Helleday T. Transcription-associated recombination is dependent on replication in mammalian cells. Mol Cell Biol 28 1 (2008) 154-164
5. Arnaudeau C., Lundin C., and Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 307 5 (2001) 1235-1245
6. Lundin C., Erixon K., Arnaudeau C., et al. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol Cell Biol 22 16 (2002) 5869-5878
7. Saleh-Gohari N., Bryant H.E., Schultz N., Parker K.M., Cassel T.N., and Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 25 16 (2005) 7158-7169
8. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 434 (2005) 913-917
9. Pan X., Ye P., Yuan D.S., Wang X., Bader J.S., and Boeke J.D. A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell 124 5 (2006) 1069-1081
10. Backus H.H., Wouters D., Ferreira C.G., et al. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 39 9 (2003) 1310-1317
11. Roninson I.B. Tumour cell senescence in cancer treatment. Cancer Res 63 11 (2003) 2705-2715
12. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
13. Kinzler K.W., and Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386 6627 (1997) 761-763
14. Schmitt C.A. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 3 4 (2003) 286-295
15. Braig M., Lee S., Loddenkemper C., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 7051 (2005) 660-665
16. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 7015 (2004) 316-323
17. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 7035 (2005) 907-913
18. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumourigenesis. Nature 434 7035 (2005) 864-870
19. Bartkova J., Rezaei N., Liontos M., et al. Oncogene-induced senescence is part of the tumourigenesis barrier imposed by DNA damage checkpoints. Nature 444 7119 (2006) 633-637
20. Di Micco R., Fumagalli M., Cicalese A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 7119 (2006) 638-642
21. Menssen A., Epanchintsev A., Lodygin D., et al. c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 6 3 (2007) 339-352
22. Bartkova J., Horejsi Z., Sehested M., et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26 53 (2007) 7414-7422
23. Sansom O.J., Meniel V.S., Muncan V., et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 446 7136 (2007) 676-679
24. Vousden K.H., and Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 8 4 (2007) 275-283
25. Mariani B.D., and Schimke R.T. Gene amplification in a single cell cycle in Chinese hamster ovary cells. J Biol Chem 259 3 (1984) 1901-1910
26. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 6712 (1998) 643-649
27. Rambach W.A., Cooper J.A., and Alt H.L. Effect of hypoxia on DNA synthesis in the bone marrow and spleen of the rat. Science 119 3090 (1954) 380-381
28. Hammond E.M., Denko N.C., Dorie M.J., Abraham R.T., and Giaccia A.J. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22 6 (2002) 1834-1843
29. Hammond E.M., Dorie M.J., and Giaccia A.J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 278 14 (2003) 12207-12213
30. Gibson S.L., Bindra R.S., and Glazer P.M. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res 65 23 (2005) 10734-10741
31. Bindra R.S., Crosby M.E., and Glazer P.M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26 2 (2007) 249-260
32. Rockwell S., Yuan J., Peretz S., and Glazer P.M. Genomic instability in cancer. Novartis Found Symp 240 (2001) 133-142 [discussion 142-151.]
33. Reynolds T.Y., Rockwell S., and Glazer P.M. Genetic instability induced by the tumour microenvironment. Cancer Res 56 24 (1996) 5754-5757
34. Hammond E.M., Dorie M.J., and Giaccia A.J. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res 64 18 (2004) 6556-6562
35. Bronner C.E., Baker S.M., Morrison P.T., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368 6468 (1994) 258-261
36. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 2 (2002) 171-182
37. Helleday T., Petermann E., Lundin C., Hodgson B., and Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8 3 (2008) 193-204
38. Jackson A.L., and Loeb L.A. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477 1-2 (2001) 7-21
39. Lehmann A.R. Translesion synthesis in mammalian cells. Exp Cell Res 312 14 (2006) 2673-2676
40. Heller R.C., and Marians K.J. Replication fork reactivation downstream of a blocked nascent leading strand. Nature 439 7076 (2006) 557-562
41. Sonoda E., Sasaki M.S., Buerstedde J.M., et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 17 2 (1998) 598-608
42. Bianchi V., Pontis E., and Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261 34 (1986) 16037-16042
43. Cobb J.A., Bjergbaek L., Shimada K., Frei C., and Gasser S.M. DNA polymerase stabilization at stalled replication forks requires Mec1 and the RecQ helicase Sgs1. EMBO J 22 16 (2003) 4325-4336
44. Lucca C., Vanoli F., Cotta-Ramusino C., et al. Checkpoint-mediated control of replisome-fork association and signalling in response to replication pausing. Oncogene 23 6 (2004) 1206-1213
45. Lopes M., Cotta-Ramusino C., Pellicioli A., et al. The DNA replication checkpoint response stabilizes stalled replication forks. Nature 412 6846 (2001) 557-561
46. Sogo J.M., Lopes M., and Foiani M. Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects. Science 297 5581 (2002) 599-602
47. Meister P., Taddei A., Vernis L., Poidevin M., Gasser S.M., and Baldacci G. Temporal separation of replication and recombination requires the intra-S checkpoint. J Cell Biol 168 4 (2005) 537-544
48. Hanada K., Budzowska M., Davies S.L., et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol (2007)
49. Sorensen C.S., Hansen L.T., Dziegielewski J., et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7 2 (2005) 195-201
50. Kumari A., Schultz N., and Helleday T. p53 protects from replication-associated DNA double-strand breaks in mammalian cells. Oncogene 23 13 (2004) 2324-2329
51. Zachos G., Rainey M.D., and Gillespie D.A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 22 3 (2003) 713-723
52. Xiao Z., Xue J., Sowin T.J., Rosenberg S.H., and Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24 8 (2005) 1403-1411
53. Rodriguez R., and Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 17 1 (2006) 402-412
54. Feijoo C., Hall-Jackson C., Wu R., et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 154 5 (2001) 913-923
55. Lomonosov M., Anand S., Sangrithi M., Davies R., and Venkitaraman A.R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev 17 24 (2003) 3017-3022
56. Moynahan M.E., Chiu J.W., Koller B.H., and Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 4 4 (1999) 511-518
57. Moynahan M.E., Pierce A.J., and Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7 2 (2001) 263-272
58. Patel K.J., Yu V.P., Lee H., et al. Involvement of Brca2 in DNA repair. Mol Cell 1 3 (1998) 347-357
59. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 7035 (2005) 917-921
60. Helleday T., Bryant H.E., and Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4 9 (2005) 1176-1178
61. Schultz N., Lopez E., Saleh-Gohari N., and Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31 17 (2003) 4959-4964
62. Fisher A., Hochegger H., Takeda S., and Caldecott K.W. Poly (ADP-ribose) polymerase-1 accelerates single-strand break repair in concert with poly (ADP-ribose) glycohydrolase. Mol Cell Biol (2007)